Lacosamide come antiepilettico in add-on in pazienti affetti da epilessia secondaria a tumore cerebrale

L. Dinapoli; M. Maschio; M. Mingoia; F. Sperati; A. Fabi; A. Pace; G. Petreri; P. Muti

Lacosamide come antiepilettico in add-on in pazienti affetti da epilessia secondaria a tumore cerebrale

Translated title of the contribution: Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability

L. Dinapoli, M. Maschio, M. Mingoia, F. Sperati, A. Fabi, A. Pace, G. Petreri, P. Muti

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min

Translated title of the contribution	Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability
Original language	Italian
Pages (from-to)	195-197
Number of pages	3
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	144
Publication status	Published - May 2012

ASJC Scopus subject areas

Clinical Neurology

Fingerprint Dive into the research topics of 'Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability'. Together they form a unique fingerprint.

Cite this

@article{63a6f14ac4ec4982ae398f51d68ce098,

title = "Lacosamide come antiepilettico in add-on in pazienti affetti da epilessia secondaria a tumore cerebrale",

abstract = "Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min ",

keywords = "Antiepileptic drugs, Brain tumor-related epilepsy, Lacosamide",

author = "L. Dinapoli and M. Maschio and M. Mingoia and F. Sperati and A. Fabi and A. Pace and G. Petreri and P. Muti",

year = "2012",

month = may,

language = "Italian",

pages = "195--197",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "144",

}

TY - JOUR

T1 - Lacosamide come antiepilettico in add-on in pazienti affetti da epilessia secondaria a tumore cerebrale

AU - Dinapoli, L.

AU - Maschio, M.

AU - Mingoia, M.

AU - Sperati, F.

AU - Fabi, A.

AU - Pace, A.

AU - Petreri, G.

AU - Muti, P.

PY - 2012/5

Y1 - 2012/5

N2 - Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min

AB - Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min

KW - Antiepileptic drugs

KW - Brain tumor-related epilepsy

KW - Lacosamide

UR - http://www.scopus.com/inward/record.url?scp=84887253483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887253483&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84887253483

SP - 195

EP - 197

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 144

ER -